of Studies With Dual Therapy With Triple Therapy With Dual Antiplatelet Therapy With Triple Therapy CI) Quality of Evidence Death (critical outcome) RCTs No serious limitations No serious inconsistency Very serious indirectness a Imprecise b Undetected RR per c more deaths per (from fewer to more) Low Nonfatal stroke (critical outcome) median follow-up y; ischemic stroke and intracranial hemorrhage RCT No serious limitations No serious inconsistency Very serious indirectness d No serious imprecision Undetected RR CHADS points Low per e fewer strokes per (from fewer to fewer) CHADS point per fewer strokes per (from fewer to fewer) CHADS points per fewer strokes per (from fewer to fewer) CHADS points per fewer strokes per (from fewer to fewer) Nonfatal MI (important outcome) RCTs No serious limitations No serious inconsistency Very serious indirectness a No serious imprecision Undetected RR per f fewer MI per (from fewer to fewer) Low Nonfatal major extracranial bleeds (important outcome) RCTs No serious limitations No serious inconsistency Very serious indirectness a No serious imprecision Undetected RR per g more bleeds per (from more to more) Moderate Systemic embolism (important outcome) median follow-up y RCT No serious limitations No serious inconsistency Very serious indirectness d No serious imprecision Undetected RR per h fewer systemic emboli per (from fewer to fewer) Low (Continued) www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e563S Table Quality Assessment Summary of Findings Risk of Bias Inconsistency Indirectness Imprecision Publication Bias Study Event Rates (%) Relative Effect CI) Estimation of Absolute Effects Time Frame No. of Studies With Dual Therapy With Triple Therapy With Dual Antiplatelet Therapy With Triple Therapy CI) Quality of Evidence Burden of treatment (important outcome) N/A No serious limitations No serious limitations No serious limitations No serious limitations N/A N/A N/A Triple therapy . 